Screener
Theravance Biopharma TBPH Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Theravance Biopharma’s 10-K, filed March 23, 2026.
- Filed
- Mar 23, 2026, 8:46 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001104659-26-033077
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Loss from operations | (3,602) | (46,949) |
| Net gain on realized contingent milestone and royalty assets | 75,137 | — |
| TRELEGY milestone income | 50,000 | — |
| Interest expense (non-cash) | (2,461) | (2,546) |
| Interest and other income, net | 10,173 | 4,881 |
| Income (loss) before income taxes | 129,247 | (44,614) |
| Provision for income tax expense | (23,352) | (11,804) |
| Net income (loss) | $105,895 | $(56,418) |
Item 16. Form 10-K Summary
FAQ
- What is Theravance Biopharma's interest expense?
- Theravance Biopharma (TBPH) reported interest expense of $582K in Q4 2025.
- How has Theravance Biopharma's interest expense changed year-over-year?
- Theravance Biopharma's interest expense decreased by 9.5% year-over-year, from $643K to $582K.
- What is the long-term trend for Theravance Biopharma's interest expense?
- Over 4 years (2021 to 2025), Theravance Biopharma's interest expense has grown at a -45.4% compound annual growth rate (CAGR), from $27.76M to $2.46M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Theravance Biopharma's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude